跳至主要内容
临床试验/NCT05080699
NCT05080699Enrolling By Invitation不适用

Effect of Hypocaloric, High-protein Enteral Formula on Body Weight and Health Outcomes in Obese HEN Patients: A Pilot Study

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2023年3月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
Mayo Clinic
入组人数
12
试验地点
1
主要终点
Change in body weight

研究概览

简要总结

The purpose of this study is to assess the effects of a low energy, high protein tube feeding formula on body weight in tube fed patients who are obese. It will also assess study formula tolerance as well as impact of the study formula on lean body mass, blood pressure, blood sugar and lipids.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Home Enteral Nutrition (HEN) patient receiving at least 90% of energy needs from enteral nutrition.
  • History of stroke.
  • Weight stable over the past month.

排除标准

  • Diagnosis of cancer undergoing active treatment (chemotherapy, radiation, immunotherapy).
  • Life expectancy of less than 6 months.
  • Stage IV or higher kidney disease (GFR < 30).

研究组 & 干预措施

Peptamen Intense in obese home enteral nutrition patients after stroke

Experimental

Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.

干预措施: Peptamen Intense VHP, Nestlé Health Science, Switzerland (Dietary Supplement)

结局指标

主要结局

Change in body weight

时间窗: Baseline, 3 months

Change in body weight, measured in kg

次要结局

  • Change in LDL(Baseline, 12 weeks)
  • Change in lean body mass(Baseline, 12 weeks)
  • Change in systolic and diastolic blood pressure(Baseline, 12 weeks)
  • Change in HbA1c(Baseline, 12 weeks)
  • Change in total cholesterol(Baseline, 12 weeks)
  • Change in c-peptide(Baseline, 12 weeks)
  • Change in HDL(Baseline, 12 weeks)
  • Change in percent goal calories provided with enteral nutrition(Baseline, 12 weeks)
  • Change in percent goal proteins provided with enteral nutrition(Baseline, 12 weeks)
  • Change in diabetes medications(Baseline, 12 weeks)
  • Change in triglycerides(Baseline, 12 weeks)
  • Change in tube feeding tolerance(Baseline, 12 weeks)
  • Change in hand grip strength(Baseline, 12 weeks)
  • Change in anti-hypertensive medications(Baseline, 12 weeks)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Manpreet S. Mundi

Principal Investigator

Mayo Clinic

研究点 (1)

Loading locations...

相似试验